Latest Quarter
Q2 FY2026ended 2026-06-30 · filed 2026-08-11
Revenue
N/A
Net Income
$-241.07M
-457.08% YoY
Operating Income
$-246.04M
-426.33% YoY
EPS (Diluted)
-$2.85
-331.82% YoY
Cash
$138.27M
Total Assets
$667.85M
Equity
$550.92M
Long-term Debt
$100K
What this quarter tells us
For Q1 FY2026 ended March 31, 2026, Mineralys Therapeutics reported no revenue and a net loss of $39.3 million, a 6.8% improvement year-over-year. Operating loss was $45.3 million, slightly wider than the prior year. Diluted EPS was -$0.47, a 40.5% improvement. The company held $112.8 million in cash and $638.1 million in equity, with no long-term debt.
- •Net loss improved 6.8% year-over-year to $39.3 million.
- •Operating loss was $45.3 million, up 2.0% from the prior year.
- •Diluted EPS improved 40.5% to -$0.47.
- •Cash and cash equivalents totaled $112.8 million with no long-term debt.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Earnings reports (12m): 4Dilution / offering filings (12m): 1Source: SEC EDGAR XBRL